Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of mRNA COVID-19 vaccine CVnCoV (Zorecimeran) in adults with comorbidities
2020-004070-22Phase 3Completed
- Sponsor
- CureVac
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of zorecimeran in coronavirus disease 2019 (COVID-19), sponsored by CureVac. Primary endpoint: Safety and reactogenicity after 1 and 2 doses of CVnCoV (Zorecimeran). Started Mar 2021; status: completed.
02
Drugs
zorecimeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-004070-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004070-22.